Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.
Kamm
Michael A
MA
Department of Gastroenterology, St. Mark's Hospital, London, United Kingdom. Kamm@ic.ac.uk
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic
D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine